Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial

Publisher： John Wiley & Sons Inc

E-ISSN： 2047-9980|4|3|JAHA.114.001349-JAHA.114.001349

ISSN： 2047-9980

Source： JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol.4, Iss.3, 2015-03, pp. : n/a-n/a

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Efficacy and safety of rivaroxaban compared with warfarin in patients with carotid artery disease and nonvalvular atrial fibrillation: Insights from the ROCKET AF trial

By  

Clinical Cardiology, Vol. 41, Iss. 1, 2018-01 ,pp. : 39-45

John Wiley & Sons Inc

Access to resources Recommend Favorite

NOAC or warfarin for Atrial Fibrillation: does time in therapeutic range matter?

By  

Recent Patents on Cardiovascular Drug Discovery, Vol. 10, Iss. 1, 2015-04 ,pp. : 60-64

Bentham Science Publishers

Access to resources Recommend Favorite

Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF‐TIMI48 Trial

By  

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 5, Iss. 2, 2016-02 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Practical issues with vitamin K antagonists: elevated INRs, low time-in-therapeutic range, and warfarin failure

By Lee Andrea   Crowther Mark  

Journal of Thrombosis and Thrombolysis, Vol. 31, Iss. 3, 2011-04 ,pp. : 249-258

Springer Publishing Company

Access to resources Recommend Favorite

Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio?

By Merli Geno   Tzanis George  

Journal of Thrombosis and Thrombolysis, Vol. 27, Iss. 3, 2009-04 ,pp. : 293-299

Springer Publishing Company

Access to resources Recommend Favorite